Changeflow GovPing Pharma & Drug Safety EPO Patent Publication EP4493556A1: NLRP3 Modul...
Routine Notice Added Final

EPO Patent Publication EP4493556A1: NLRP3 Modulators

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Pharma (A61K)
Published March 18th, 2026
Detected March 24th, 2026
Email

Summary

The European Patent Office (EPO) published patent application EP4493556A1 on March 18, 2026, related to NLRP3 modulators. The patent application lists Zomagen Biosciences Ltd as the applicant.

What changed

The European Patent Office (EPO) has published patent application EP4493556A1, concerning NLRP3 modulators. The publication date is March 18, 2026, and the applicant is Zomagen Biosciences Ltd. This publication details potential new therapeutic agents and their applications, as indicated by the extensive IPC classifications covering various medical conditions.

This patent publication is primarily an informational notice for the pharmaceutical and biotechnology sectors. It does not impose immediate compliance obligations but serves as a notification of intellectual property filings. Companies operating in drug development, particularly those researching inflammatory or metabolic diseases, should note this filing as it may impact future competitive landscapes or licensing opportunities.

Source document (simplified)

← EPO Patent Bulletin

NLRP3 MODULATORS

Publication EP4493556A1 Kind: A1 Mar 18, 2026

Applicants

Zomagen Biosciences Ltd

Inventors

COLLINS, James, BOLLU, Venkat, YUAN, Shendong, NUSS, John

IPC Classifications

C07D 403/06 20060101AFI20240917BHEP A61K 31/501 20060101ALI20240917BHEP A61K 31/502 20060101ALI20240917BHEP A61K 31/55 20060101ALI20240917BHEP A61P 1/04 20060101ALI20240917BHEP A61P 1/16 20060101ALI20240917BHEP A61P 3/00 20060101ALI20240917BHEP A61P 3/04 20060101ALI20240917BHEP A61P 3/10 20060101ALI20240917BHEP A61P 9/00 20060101ALI20240917BHEP A61P 9/10 20060101ALI20240917BHEP A61P 11/00 20060101ALI20240917BHEP A61P 11/06 20060101ALI20240917BHEP A61P 17/06 20060101ALI20240917BHEP A61P 19/06 20060101ALI20240917BHEP A61P 25/08 20060101ALI20240917BHEP A61P 25/16 20060101ALI20240917BHEP A61P 25/24 20060101ALI20240917BHEP A61P 25/28 20060101ALI20240917BHEP A61P 37/00 20060101ALI20240917BHEP C07D 413/06 20060101ALI20240917BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4493556A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development Patent Filing
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property Drug Development

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.